Literature DB >> 18765137

Neuromodulators for the treatment of headache disorders and fibromyalgia.

Abouch V Krymchantowski1, Juline Bryson, Richard B Lipton, Marcelo E Bigal.   

Abstract

Migraine and fibromyalgia are prevalent and disabling disorders with few preventive medications approved by the US Food and Drug Administration (FDA). Neuromodulators (or antiepileptic drugs; AEDs) are often effective in the treatment of these conditions. Divalproex sodium and topiramate are FDA-approved AEDs for migraine. For fibromyalgia, pregabalin has recently been approved in the United States. We review the use of AEDs in the preventive treatment of these highly prevalent disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18765137     DOI: 10.1007/s11916-008-0056-8

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  44 in total

Review 1.  Prophylactic migraine therapy: mechanisms and evidence.

Authors:  Nabih M Ramadan
Journal:  Curr Pain Headache Rep       Date:  2004-04

2.  Pregabalin for pain management.

Authors:  Noor M Gajraj
Journal:  Pain Pract       Date:  2005-06       Impact factor: 3.183

3.  Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors.

Authors:  W F Stewart; R B Lipton; D D Celentano; M L Reed
Journal:  JAMA       Date:  1992-01-01       Impact factor: 56.272

Review 4.  Mechanisms of disease: pain in fibromyalgia syndrome.

Authors:  Roland Staud; Miguel E Rodriguez
Journal:  Nat Clin Pract Rheumatol       Date:  2006-02

5.  Brain stem activation in spontaneous human migraine attacks.

Authors:  C Weiller; A May; V Limmroth; M Jüptner; H Kaube; R V Schayck; H H Coenen; H C Diener
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

6.  Efficacy of gabapentin in migraine prophylaxis.

Authors:  N T Mathew; A Rapoport; J Saper; L Magnus; J Klapper; N Ramadan; B Stacey; S Tepper
Journal:  Headache       Date:  2001-02       Impact factor: 5.887

Review 7.  Basic mechanisms in vascular headache.

Authors:  M A Moskowitz
Journal:  Neurol Clin       Date:  1990-11       Impact factor: 3.806

8.  Effects of the N-methyl-D-aspartate receptor antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal control subjects.

Authors:  Roland Staud; Charles J Vierck; Michael E Robinson; Donald D Price
Journal:  J Pain       Date:  2005-05       Impact factor: 5.820

Review 9.  An overview of the diagnosis and pharmacologic treatment of migraine.

Authors:  D J Capobianco; W P Cheshire; J K Campbell
Journal:  Mayo Clin Proc       Date:  1996-11       Impact factor: 7.616

10.  Migraine prophylaxis with divalproex.

Authors:  N T Mathew; J R Saper; S D Silberstein; L Rankin; H G Markley; S Solomon; A M Rapoport; C J Silber; R L Deaton
Journal:  Arch Neurol       Date:  1995-03
View more
  1 in total

1.  Prophylatic treatment of migraine and migraine clinical variants with topiramate: an update.

Authors:  Sergio Carmona; Osvaldo Bruera
Journal:  Ther Clin Risk Manag       Date:  2009-08-20       Impact factor: 2.423

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.